HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

Histone deacetylase (HDAC) inhibitors have been demonstrated to be beneficial in animal models of neurodegenerative diseases. Such results were mainly associated with the epigenetic modulation caused by HDACs, especially those from class I, via chromatin deacetylation. However, other mechanisms may...

Descripción completa

Detalles Bibliográficos
Autores principales: Simões-Pires, Claudia, Zwick, Vincent, Nurisso, Alessandra, Schenker, Esther, Carrupt, Pierre-Alain, Cuendet, Muriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615964/
https://www.ncbi.nlm.nih.gov/pubmed/23356410
http://dx.doi.org/10.1186/1750-1326-8-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615964/
https://www.ncbi.nlm.nih.gov/pubmed/23356410
http://dx.doi.org/10.1186/1750-1326-8-7

Ejemplares similares